Lantheus provides innovative diagnostics, targeted therapeutics and artificial intelligence (AI) solutions that empower clinicians to Find, Fight and Follow® disease. For more than 60 years, Lantheus has delivered life-changing science to patients and providers, going further to improve outcomes and lives.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden.
Lantheus provides a broad portfolio of products, including PYLARIFY® (Piflufolastat F18), a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the evaluation of PSMA PET images; DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound enhancing agent for patients with suboptimal echocardiograms; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and AZEDRA® (Iobenguane I 131) for the treatment of certain rare neuroendocrine tumors.
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
September 13, 2022
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary endpoint, demonstrating higher diagnostic efficacy f...
Lantheus to Present at the Wells Fargo Healthcare Conference
September 1, 2022
NORTH BILLERICA, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative diagnostics, targeted therapeutics and artificial i...
Lantheus Reports Second Quarter 2022 Financial Results
August 4, 2022
Worldwide revenue of $223.7 million for the second quarter 2022, representing an increase of 121.4% from the prior year period GAAP net income of $43.1 million for the second quarter 2022, compared to GAAP net loss of $26.7 million in the pri...
Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern Time
July 21, 2022
NORTH BILLERICA, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 4, 2022, to discuss its finan...
Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations NORTH BILLERICA, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced two key management promoti...
Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer
June 13, 2022
Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting NORTH BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH) is committed to improving...